JNJ•Johnson & Johnson said CARVYKTI delivered five-year treatment-free remission in 50% of CARTITUDE-2 cohort A patients. The long-term results were presented at the International Myeloma Society annual meeting.
Johnson & Johnson disclosed long-term CARTITUDE-2 data showing CARVYKTI delivered sustained treatment-free remissions for many early-line relapsed myeloma patients. The findings support moving the CAR-T therapy earlier in care, aiming for greater durability without ongoing maintenance therapy; longer-term safety remained broadly consistent with prior experience, with no new CAR-T neurotoxicity signals flagged.
